Nalaganje...
Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100
PURPOSE: No biomarkers have been identified to predict outcome with the use of an antiangiogenesis agent for cancer. Vascular endothelial growth factor (VEGF) genetic variability has been associated with altered risk of breast cancer and variable promoter activity. Therefore, we evaluated the associ...
Shranjeno v:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
American Society of Clinical Oncology
2008
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2653128/ https://ncbi.nlm.nih.gov/pubmed/18824714 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.16.1612 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|